Ghent, BELGIUM – 15 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in the following upcoming virtual investor conferences. BTIG Virtual MedTech, Digital Health, Life Science &...Read More